Prothena Corporation Plc (PRTA) 69.11 $PRTA 3 Long Shots

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 3:11 PM

Prothena Corporation Plc (PRTA) 69.11 $PRTA

3 Long Shots Biotech Companies Are Working On
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 10, 4:04PM CDT
Source: Flickr user Micolo J. The Holy Grail of biotech companies is a billion-dollar blockbuster therapy, but more often than not, efforts to invent game-changing medicines that can eclipse the billion-dollar threshold fall short. That's...
BIIB: 319.37 (+9.94), PRTA: 69.11 (+6.34)

Why Shares of Prothena Surged 33% Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 10:02AM CDT
Source: Prothena Corp. Plc Compelling early stage trial data for Prothena Corp. Plc 's PRX002 as a therapy for Parkinson's disease sent the company's shares soaring 33.5% in June. Offering new hope Prothena is developing PRX002 with ...
PRTA: 69.11 (+6.34)

10 Best Biotech Stocks in the NASDAQ
at The Street - Wed Jul 01, 10:23AM CDT
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
SGYP: 8.14 (-0.05), HALO: 23.72 (+0.92), RARE: 120.07 (+3.01), KYTH: 74.52 (+0.17), RTRX: 32.93 (+1.08), IMGN: 18.06 (+0.64), HZNP: 38.14 (+2.01), ANAC: 151.69 (+7.39), PRTA: 69.11 (+6.34), EXEL: 5.43 (-0.01)

Prothena Announces Addition of Seasoned Executive to Board of Directors
Thomson Reuters ONE - Mon Jun 29, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 69.11 (+6.34)

5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 33.60 (+1.30), XBI: 257.75 (+5.97), RTRX: 32.93 (+1.08), EGRX: 92.40 (+1.17), PRTA: 69.11 (+6.34), EXEL: 5.43 (-0.01)

5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 33.60 (+1.30), XBI: 257.75 (+5.97), RTRX: 32.93 (+1.08), EGRX: 92.40 (+1.17), PRTA: 69.11 (+6.34), EXEL: 5.43 (-0.01)

Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 337.62 (+10.64), ACAD: 49.26 (+1.70), KYTH: 74.52 (+0.17), TKMR: 10.28 (-0.02), AMGN: 174.12 (+8.58), AERI: 19.07 (+0.52), TEVA: 70.95 (-1.05), LLY: 85.58 (+1.43), PRTA: 69.11 (+6.34), NVS: 102.80 (+1.26), HCC: 77.22 (+0.04)

The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT

AGEN: 8.29 (-0.10), CRIS: 3.15 (-0.02), TTPH: 48.17 (-0.55), XBI: 257.75 (+5.97), IBB: 382.35 (+8.77), ABBV: 70.98 (+1.64), EGRX: 92.40 (+1.17), PRTA: 69.11 (+6.34), CELG: 135.72 (+3.16)

Prothena's PRX002 knocks down PD-related protein 96% in early stage study
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 7:15AM CDT

PRTA: 69.11 (+6.34)

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002...
Thomson Reuters ONE - Wed Jun 17, 6:00AM CDT
- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 69.11 (+6.34)

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
GlobeNewswire - Wed Jun 17, 6:00AM CDT
-- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 69.11 (+6.34)

Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
Thomson Reuters ONE - Tue Jun 16, 3:06PM CDT
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at the JMP Securities Life Science Conference 2015 on June 23 at 10 a.m. EDT at The St. Regis in New York, NY.
PRTA: 69.11 (+6.34)

Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:05AM CDT
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of Stanford University School of Medicine presented data from the ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction in an oral presentation (Abstract #S104) during the 20th Congress of the European Hematology Association (EHA) in Vienna.
PRTA: 69.11 (+6.34)

Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:00AM CDT
- 72% of Survey Respondents had AL Amyloidosis
PRTA: 69.11 (+6.34)

Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 10, 2:35PM CDT
Prothena Corporation plc (PRTA) dosed the first patient in a phase I study on PRX003 for the potential treatment of psoriasis and other inflammatory diseases.
VRX: 257.45 (+0.15), PRTA: 69.11 (+6.34)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...